JPWO2021216775A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021216775A5 JPWO2021216775A5 JP2022563869A JP2022563869A JPWO2021216775A5 JP WO2021216775 A5 JPWO2021216775 A5 JP WO2021216775A5 JP 2022563869 A JP2022563869 A JP 2022563869A JP 2022563869 A JP2022563869 A JP 2022563869A JP WO2021216775 A5 JPWO2021216775 A5 JP WO2021216775A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- nucleic acid
- epitope
- encoding nucleic
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical group 0.000 claims description 346
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 259
- 239000000203 mixture Substances 0.000 claims description 219
- 239000002773 nucleotide Substances 0.000 claims description 187
- 125000003729 nucleotide group Chemical group 0.000 claims description 187
- 239000000427 antigen Substances 0.000 claims description 151
- 108091007433 antigens Proteins 0.000 claims description 151
- 102000036639 antigens Human genes 0.000 claims description 151
- 239000013598 vector Substances 0.000 claims description 129
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 116
- 210000004027 cell Anatomy 0.000 claims description 98
- 238000000034 method Methods 0.000 claims description 78
- 108091034057 RNA (poly(A)) Proteins 0.000 claims description 69
- 102000043131 MHC class II family Human genes 0.000 claims description 41
- 108091054438 MHC class II family Proteins 0.000 claims description 41
- 108091081062 Repeated sequence (DNA) Proteins 0.000 claims description 35
- 102000043129 MHC class I family Human genes 0.000 claims description 34
- 108091054437 MHC class I family Proteins 0.000 claims description 34
- 229960005486 vaccine Drugs 0.000 claims description 32
- 150000001413 amino acids Chemical class 0.000 claims description 29
- 244000052769 pathogen Species 0.000 claims description 28
- 108700028369 Alleles Proteins 0.000 claims description 27
- 208000015181 infectious disease Diseases 0.000 claims description 26
- 230000028993 immune response Effects 0.000 claims description 25
- 206010028980 Neoplasm Diseases 0.000 claims description 24
- 208000035473 Communicable disease Diseases 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 210000004881 tumor cell Anatomy 0.000 claims description 19
- 108091027544 Subgenomic mRNA Proteins 0.000 claims description 15
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 claims description 15
- 238000012217 deletion Methods 0.000 claims description 14
- 230000037430 deletion Effects 0.000 claims description 14
- 229920001184 polypeptide Polymers 0.000 claims description 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 238000012163 sequencing technique Methods 0.000 claims description 14
- 230000004075 alteration Effects 0.000 claims description 13
- 230000008488 polyadenylation Effects 0.000 claims description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 12
- 241000710929 Alphavirus Species 0.000 claims description 12
- 241000894006 Bacteria Species 0.000 claims description 11
- 241000233866 Fungi Species 0.000 claims description 11
- 241000700605 Viruses Species 0.000 claims description 11
- 244000045947 parasite Species 0.000 claims description 11
- 230000001717 pathogenic effect Effects 0.000 claims description 11
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 10
- 238000000338 in vitro Methods 0.000 claims description 10
- 230000037452 priming Effects 0.000 claims description 10
- 230000001225 therapeutic effect Effects 0.000 claims description 10
- 238000013518 transcription Methods 0.000 claims description 10
- 230000035897 transcription Effects 0.000 claims description 10
- 230000003321 amplification Effects 0.000 claims description 9
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 241000178568 Aura virus Species 0.000 claims description 8
- 206010066919 Epidemic polyarthritis Diseases 0.000 claims description 8
- 241000231322 Fort Morgan virus Species 0.000 claims description 8
- 241000608292 Mayaro virus Species 0.000 claims description 8
- 241000710942 Ross River virus Species 0.000 claims description 8
- 241000710961 Semliki Forest virus Species 0.000 claims description 8
- 241000710960 Sindbis virus Species 0.000 claims description 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 8
- 230000004936 stimulating effect Effects 0.000 claims description 8
- 241000282577 Pan troglodytes Species 0.000 claims description 7
- 230000001404 mediated effect Effects 0.000 claims description 7
- 238000013519 translation Methods 0.000 claims description 7
- 230000035772 mutation Effects 0.000 claims description 6
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 210000004443 dendritic cell Anatomy 0.000 claims description 5
- 101710094648 Coat protein Proteins 0.000 claims description 4
- 108700026244 Open Reading Frames Proteins 0.000 claims description 4
- 231100000221 frame shift mutation induction Toxicity 0.000 claims description 4
- 230000037433 frameshift Effects 0.000 claims description 4
- 230000003053 immunization Effects 0.000 claims description 4
- 238000002649 immunization Methods 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- 238000003780 insertion Methods 0.000 claims description 4
- 230000037431 insertion Effects 0.000 claims description 4
- 238000007481 next generation sequencing Methods 0.000 claims description 4
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 3
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims description 3
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims description 3
- 125000000539 amino acid group Chemical group 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000004949 mass spectrometry Methods 0.000 claims description 3
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 2
- 108020003589 5' Untranslated Regions Proteins 0.000 claims description 2
- 101710128560 Initiator protein NS1 Proteins 0.000 claims description 2
- 101710144127 Non-structural protein 1 Proteins 0.000 claims description 2
- 108010029485 Protein Isoforms Proteins 0.000 claims description 2
- 102000001708 Protein Isoforms Human genes 0.000 claims description 2
- 101800001758 RNA-directed RNA polymerase nsP4 Proteins 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 230000006472 autoimmune response Effects 0.000 claims description 2
- 210000000234 capsid Anatomy 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 102000054766 genetic haplotypes Human genes 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 claims description 2
- 230000008707 rearrangement Effects 0.000 claims description 2
- 101800000515 Non-structural protein 3 Proteins 0.000 claims 1
- 101800000980 Protease nsP2 Proteins 0.000 claims 1
- 230000008569 process Effects 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 description 40
- 239000012634 fragment Substances 0.000 description 17
- 201000011510 cancer Diseases 0.000 description 9
- 241000701022 Cytomegalovirus Species 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000002519 immonomodulatory effect Effects 0.000 description 8
- 241001217856 Chimpanzee adenovirus Species 0.000 description 6
- 241000711573 Coronaviridae Species 0.000 description 6
- 241000711549 Hepacivirus C Species 0.000 description 6
- 241000701806 Human papillomavirus Species 0.000 description 6
- 241000725643 Respiratory syncytial virus Species 0.000 description 6
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 6
- 229960000814 tetanus toxoid Drugs 0.000 description 6
- 241000700721 Hepatitis B virus Species 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 108090000848 Ubiquitin Proteins 0.000 description 4
- 102000044159 Ubiquitin Human genes 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 3
- 208000003950 B-cell lymphoma Diseases 0.000 description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 3
- 102000014944 Lysosome-Associated Membrane Glycoproteins Human genes 0.000 description 3
- 108010064171 Lysosome-Associated Membrane Glycoproteins Proteins 0.000 description 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 3
- 241000712464 Orthomyxoviridae Species 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 206010038389 Renal cancer Diseases 0.000 description 3
- 206010041067 Small cell lung cancer Diseases 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 208000000389 T-cell leukemia Diseases 0.000 description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 description 3
- 206010057644 Testis cancer Diseases 0.000 description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 201000010536 head and neck cancer Diseases 0.000 description 3
- 208000014829 head and neck neoplasm Diseases 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 201000010982 kidney cancer Diseases 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 201000003120 testicular cancer Diseases 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- 201000009182 Chikungunya Diseases 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 208000001490 Dengue Diseases 0.000 description 2
- 206010012310 Dengue fever Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- -1 amino lipid Chemical class 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 208000025729 dengue disease Diseases 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- OGHAROSJZRTIOK-KQYNXXCUSA-O 7-methylguanosine Chemical compound C1=2N=C(N)NC(=O)C=2[N+](C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OGHAROSJZRTIOK-KQYNXXCUSA-O 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241001502567 Chikungunya virus Species 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 102000004961 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 1
- NRLNQCOGCKAESA-KWXKLSQISA-N [(6z,9z,28z,31z)-heptatriaconta-6,9,28,31-tetraen-19-yl] 4-(dimethylamino)butanoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC\C=C/C\C=C/CCCCC NRLNQCOGCKAESA-KWXKLSQISA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000014619 adult acute lymphoblastic leukemia Diseases 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 210000000852 deltoid muscle Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000025308 nuclear transport Effects 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000003314 quadriceps muscle Anatomy 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000002374 tyrosine Nutrition 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063013466P | 2020-04-21 | 2020-04-21 | |
| US63/013,466 | 2020-04-21 | ||
| PCT/US2021/028485 WO2021216775A2 (en) | 2020-04-21 | 2021-04-21 | Antigen-encoding cassettes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023523413A JP2023523413A (ja) | 2023-06-05 |
| JPWO2021216775A5 true JPWO2021216775A5 (https=) | 2024-05-01 |
| JP2023523413A5 JP2023523413A5 (https=) | 2024-05-01 |
Family
ID=78269964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022563869A Pending JP2023523413A (ja) | 2020-04-21 | 2021-04-21 | 抗原コードカセット |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230310563A1 (https=) |
| EP (1) | EP4138890A4 (https=) |
| JP (1) | JP2023523413A (https=) |
| KR (1) | KR20230014694A (https=) |
| CN (1) | CN115803049A (https=) |
| AU (1) | AU2021258191A1 (https=) |
| CA (1) | CA3173905A1 (https=) |
| IL (1) | IL296854A (https=) |
| WO (1) | WO2021216775A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019013259A (es) | 2017-05-08 | 2020-01-13 | Gritstone Oncology Inc | Vectores de neoantigeno de alfavirus. |
| MX2021014525A (es) | 2019-05-30 | 2022-03-17 | Gritstone Bio Inc | Adenovirus modificados. |
| KR20230046313A (ko) | 2020-08-06 | 2023-04-05 | 그릿스톤 바이오, 인코포레이티드 | 다중에피토프 백신 카세트 |
| WO2025028960A1 (ko) * | 2023-07-28 | 2025-02-06 | 주식회사 엘지화학 | 항원 전달용 컨쥬게이트 및 이의 이용 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6514731B1 (en) * | 1996-05-24 | 2003-02-04 | Chiron Corporation | Methods for the preparation of hepatitis C virus multiple copy epitope fusion antigens |
| JP2002536008A (ja) * | 1999-02-11 | 2002-10-29 | ジェンザイム・コーポレーション | 抗原ペプチドコンカテマー |
| CA2394741A1 (en) * | 1999-12-21 | 2001-06-28 | Epimmune Inc. | Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions |
| MX2007015933A (es) * | 2005-06-17 | 2008-04-21 | Mannkind Corp | Metodos y composiciones para generar respuestas inmunes multivalentes contra espitopes dominantes y subdominantes, expresados en celulas cancerigenas y estromas tumorales. |
| CN101721698B (zh) * | 2008-10-24 | 2014-04-02 | 法罗斯疫苗公司 | 抗口蹄疫疫苗组合物及其制备和应用 |
| CA2828068C (en) * | 2011-02-22 | 2019-03-19 | Biondvax Pharmaceuticals Ltd. | Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines |
| AU2017226199A1 (en) * | 2016-03-04 | 2018-09-13 | New York University | Virus vectors expressing multiple epitopes of tumor associated antigens for inducing antitumor immunity |
| CN112368386A (zh) * | 2018-05-23 | 2021-02-12 | 磨石肿瘤生物技术公司 | 共有抗原 |
| CN110003314B (zh) * | 2019-04-11 | 2023-06-09 | 上海市计划生育科学研究所 | H1n1流感病毒血凝素可诱发广谱保护性抗体的表位肽及其应用 |
-
2021
- 2021-04-21 AU AU2021258191A patent/AU2021258191A1/en active Pending
- 2021-04-21 IL IL296854A patent/IL296854A/en unknown
- 2021-04-21 JP JP2022563869A patent/JP2023523413A/ja active Pending
- 2021-04-21 WO PCT/US2021/028485 patent/WO2021216775A2/en not_active Ceased
- 2021-04-21 KR KR1020227040441A patent/KR20230014694A/ko active Pending
- 2021-04-21 CN CN202180043892.1A patent/CN115803049A/zh active Pending
- 2021-04-21 EP EP21793392.8A patent/EP4138890A4/en active Pending
- 2021-04-21 CA CA3173905A patent/CA3173905A1/en active Pending
-
2022
- 2022-10-20 US US18/048,403 patent/US20230310563A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021525076A5 (https=) | ||
| JPWO2019226941A5 (https=) | ||
| JP2021524247A5 (https=) | ||
| AU699384B2 (en) | Alphavirus cDNA vectors | |
| Gardner et al. | Infection of human dendritic cells by a sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein | |
| JP2021501572A5 (https=) | ||
| RU2019119272A (ru) | Вирусная доставка неоантигенов | |
| JPWO2021236854A5 (https=) | ||
| JP2021524247A (ja) | 免疫チェックポイント阻害剤の共発現ベクター | |
| JP2022512912A (ja) | アルファウイルス新生抗原ベクター及びインターフェロン阻害因子 | |
| AU3427100A (en) | Stable recombinant influenza viruses free of helper viruses | |
| McAllister et al. | Recombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases | |
| FI3652606T3 (fi) | Jaettuihin tuumorineoantigeeneihin perustuva yleisrokote epästabiilien mikrosatelliitti (msi) -syöpien ennaltaehkäisyyn ja hoitoon | |
| JPWO2012053646A1 (ja) | ワクシニアウイルスベクターおよびセンダイウイルスベクターからなるプライム／ブーストワクチン用ウイルスベクター | |
| CN114854773A (zh) | 顺式复制子构建体 | |
| JP2004501646A5 (https=) | ||
| JPWO2020097393A5 (https=) | ||
| JPWO2019226939A5 (https=) | ||
| CN118086288B (zh) | 多顺反子的自放大rna及制备方法 | |
| JP2005508610A (ja) | 異種タンパク質の製造に有用なプラス鎖ｒｎａウイルスゲノムに由来するレプリコン | |
| JP2025502689A (ja) | タンパク質発現のためのｍＲＮＡ及びそのための鋳型 | |
| JPWO2022032196A5 (https=) | ||
| WO2023227124A1 (zh) | 一种构建mRNA体外转录模板的骨架 | |
| JPWO2020243719A5 (https=) | ||
| WO2025102994A1 (zh) | 基于i型内含子的rna体外环化与滚环翻译的方法及其应用 |